The options may be chosen on the product page DSIP 49,95 399,95Price range: 49,95 through 399,95 Inclusief BTW Select options This product has multiple variants
A compound of unknown purity administered to a human body introduces risks entirely separate from the compounds own pharmacological profile
Oliai Araghi S, Kiefte-de Jong JC, van Dijk SC, Swart KMA, van Laarhoven HW, van Schoor NM, de Groot LCPGM, Lemmens V, Stricker BH, Uitterlinden AG, van der Velde N
Active infections: Peptide therapy during active infections is not recommended, as the immune-modulating effects could theoretically interfere with the body response to the infection
This Phase 2b failure effectively terminated clinical development for obesity